Document text
Principal Investigator: Pari Vijay Pandharipande
Organization: OHIO STATE UNIVERSITY
Fiscal Year: 2024
Award: $394,049
Funding agency: National Cancer Institute
PROJECT SUMMARY/ABSTRACT
Our goal is to find the best ways to prevent pancreatic cancer deaths in patients with pancreatic cysts. Recent
advances in imaging have led to the detection of innumerable pancreatic cysts that could never be seen
before, now visible in >10% of patients who have an MRI and in >2% who have a CT scan for an unrelated
reason. When such cysts are unexpected and asymptomatic, they are considered “incidental.” The majority
represent intraductal papillary mucinous neoplasms (IPMNs), which are indolent precursors to Pancreatic
Ductal AdenoCarcinoma (PDAC), the most common type of pancreatic cancer. Given the poor prognosis and
survival of patients with PDAC, pancreatic cysts have become a primary target of early PDAC detection.
Imaging surveillance is advised for most patients who are diagnosed with an incidental pancreatic cyst, but key
factors that define surveillance – e.g., the frequency, modality, and duration of imaging, and when to pursue
biopsy or surgery – are highly controversial. Critics of intensive surveillance raise concerns about overtesting
and overtreatment, particularly given that many patients with such cysts are older and have comorbidities.
Advocates emphasize the singular opportunity for early PDAC detection that arises from close monitoring.
To address this problem, we will build a computer-based simulation model that replicates the natural history of
incidental pancreatic cysts, and use it to formulate a precision management approach. Our research plan will
draw from our team’s existing simulation model of PDAC, which is calibrated to data from the National Cancer
Institute’s Surveillance, Epidemiology, and End Results (SEER) Program and published studies. First, we will
extend this model to replicate the natural history of incidentally detected pancreatic cysts (Aim 1). We will then
use the model to identify effective (Aim 2) and cost-effective (Aim 3) management strategies that are tailored to
both cyst features (size, complexity) and patient characteristics (age, comorbidity status). Finally, we will
evaluate the potential for emerging blood and cyst-fluid biomarkers to further improve management (Aim 4).
The proposed research is innovative because it applies an advanced modeling approach to a controversial
problem that will be difficult to solve with observational studies or clinical trials alone. The research team is
well-suited, with an established track record in pancreatic cancer care and incidental pancreatic cysts, and with
substantial experience in developing mathematical models that have been used to inform health policy at
national levels. The results will be threefold: 1) a detailed natural history model of incidental pancreatic cysts;
2) a tailored approach to their management, based on cyst features and patient characteristics; and 3) a
roadmap for advancing future research in cystic precursors to pancreatic cancer in the coming years.
Terms: <Address><Advocate><Affect><Age><Biological Markers><Biopsy><Blood><Blood Reticuloendothelial System><CAT scan><CT X Ray><CT Xray><CT imaging><CT scan><Calibration><Cancer Cause><Cancer Control><Cancer Control Science><Cancer Etiology><Cessation of life><Characteristics><Clinical><Clinical Trials><Clinical Trials Design><Complement><Complement Proteins><Computed Tomography><Computer Simulation><Computer based Simulation><Cost Effectiveness Analysis><Cyst><Cyst Fluid><Data><Data Sources><Death><Detection><Diagnosis><Endoscopic Ultrasonography><Equilibrium><Frequencies><Future><General Hospitals><Goals><Guidelines><Harm Minimization><Harm Reduction><Health><Health Insurance for Aged and Disabled, Title 18><Health Insurance for Disabled Title 18><Health Policy><Image><Indolent><Intervention><Intervention Strategies><Life Expectancy><Link><Literature><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Malignant Pancreatic Neoplasm><Malignant neoplasm of pancreas><Massachusetts><Math Models><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medical Societies><Medicare><Methods><Modality><Modeling><Monitor><Mucinous Neoplasm><Mucinous Tumor><NCI Organization><NMR Imaging><NMR Tomography><National Cancer Institute><Natural History><Nuclear Magnetic Resonance Imaging><Observation research><Observation study><Observational Study><Observational research><Operative Procedures><Operative Surgical Procedures><Outcomes Research><PDA model><PDAC Model><Pancreas Cancer><Pancreas Cyst><Pancreas Ductal Adenocarcinoma><Pancreas Excision><Pancreatectomy><Pancreatic Cancer><Pancreatic Cyst><Pancreatic Ductal Adenocarcinoma><Papillary><Pathway interactions><Patient Care><Patient Care Delivery><Patients><Personalized medical approach><Prognosis><Publishing><Recommendation><Reporting><Research><Risk><SEER Program><SEER-Surveillance, Epidemiology, and End Results><Serous Cystadenoma><Serous Cystoma><Surgical><Surgical Interventions><Surgical Procedure><Surveillance, Epidemiology and End Results><Surveillance, Epidemiology, and End Results Program><Title 18><Tomodensitometry><X-Ray CAT Scan><X-Ray Computed Tomography><X-Ray Computerized Tomography><Xray CAT scan><Xray Computed Tomography><Xray computerized tomography><Zeugmatography><ages><balance><balance function><bio-markers><biologic marker><biomarker><cancer care><cancer invasiveness><care for patients><care of patients><caring for patients><catscan><co-morbid><co-morbidity><comorbidity><complementation><computational simulation><computed axial tomography><computer tomography><computerized axial tomography><computerized simulation><computerized tomography><cost><cost effective><cost efficient analysis><cost estimate><cost estimation><cost-effective analysis><death risk><elderly patient><endoscopic ultrasound><experience><health care policy><health insurance for disabled><healthcare policy><imaging><improved><individualized approach><individualized management><individualized patient management><innovate><innovation><innovative><interventional strategy><mathematic model><mathematical model><mathematical modeling><model-based simulation><models and simulation><mortality risk><non-contrast CT><noncontrast CT><noncontrast computed tomography><older patient><over-treatment><overtreatment><pancreas surgery><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic surgery><pathway><patient population><personalized approach><personalized clinical management><personalized disease management><personalized management><precision approach><precision management><prevent><preventing><surgery><surveillance imaging><tailored approach>